An observational study in Diabetes Mellitus, sponsored by Asan Medical Center. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-03-30.
Sponsored by Asan Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 224 studies in Diabetes Mellitus with a site in Korea, Republic of — 22 open to participants now, 25 under way, 3 of them phase 3. Diabetes Mellitus · Korea, Republic of.
Among the 224 studies in Diabetes Mellitus with a site in Korea, Republic of, this one is the 29th largest by planned enrollment of the 43 observational ones that give a count, is one of 4 that started in 2021, is one of 43 observational ones, reaches primary completion later than 14 of the 24 other live ones, and was the 194th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →22 of the 224 studies in Diabetes Mellitus with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Pfizer · Sites in Korea, Republic of, United States, Brazil and 8 more countries
Ages 18+
VUNO Inc. · Sites in Korea, Republic of
Ages 19+
Sin Gon Kim · Sites in Korea, Republic of
Ages 70+
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
224 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 7 · Phase 3 51 · Phase 4 48
First in 2001; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 511 is above the median of 246 across 1,935 observational studies indexed under Diabetes Mellitus.
Median enrollment 140 across the 181 interventional studies, 1,030 across the 43 observational. Of the 175 that completed or were terminated, 55 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 224 have an industry lead sponsor. The 10 most frequent:
Asan Medical Center is the lead sponsor of 578 studies on the registry; 72 are open to participants now.
Asan Medical Center has 2 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
4 of the studies in Diabetes Mellitus with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07239440Dong-A ST Co., Ltd.Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control | 2026-12 |
| NCT05801432Asan Medical CenterA Study to Evaluate Coronary Atherosclerosis in Patients With Diabetes Mellitus | 2026-12-31 |
| NCT05149625Seoul National University HospitalComparison of the Efficacy and Satisfaction of Blood Glucose Management Between Continuous Glucose Monitoring Versus Traditional Self-blood Glucose Measurement in Diabetic Patients After Pancreatectomy | 2026-12-31 |
| NCT07378956VUNO Inc.Clinical Efficacy of Implementing an AI-SaMD for Funduscopy Analysis in Patients With Diabetes Mellitus | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 224 studies in Diabetes Mellitus with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the natural history of coronary atherosclerosis development and progression over time by CCTA and to identify risk factors attributable to the development of coronary atherosclerosis in a Korean DM population.
Patients with diabetes mellitus, who underwent initial CCTA (coronary computed tomographic angiography) at the Diabetes Center of the Asan Medical Center between February 2008 and June 2012, will be evaluated for inclusion in the study. All DREAM-CCTA study patients will undergo follow-up CCTA based on order from their primary physician. CCTA and demographic data, medical history, cardiovascular risk factors, and laboratory data was collected in case report forms at the time of the initial CCTA and at the time of follow-up CCTA.
About 511 consecutive asymptomatic patients with type 2 DM, who had undergone initial CCTA evaluation at the Diabetes Center of the Asan Medical Center between February 2008 and June 2012, will be screened for enrollment in this study. A member of research team should review the patients' medical history for eligibility. If all eligibility criteria are met and written informed consent is provided, the patient may be enrolled in the study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The change in coronary atherosclerosis detected by initial and follow-up CCTA
the natural history of coronary atherosclerotic plaque development and progression over time by CCTA
Time frame: about 10 years after first CCTA
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2021 (actual). Primary completion is estimated for Dec 2026, 64 months after the start.
Of 534 non-industry observational studies under Diabetes Mellitus, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 159. This study's planned 64 months is above that.
Counting every sponsor, half of 643 studies reached it within 36 months; a quarter within 14 and three quarters within 122.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.